| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | President and CEO
2 companies
Christophe Pierre Weber is President and CEO at TKPHF, with reported holdings spanning 2 companies. Christophe Pierre Weber's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $17.8M at current prices.
Christophe Pierre Weber's largest disclosed position is in TKPHF as President and CEO, worth about $17.6M.
Christophe Pierre Weber has 3 Form 4 filings on record from March 2026 to May 2026, across 2 companies: Director at Boston Scientific (BSX), 2026; President and CEO at Takeda Pharmaceutical (TKPHF), 2026.
The 8 reported transactions were 6 stock awards and 2 option or other derivative awards.
There are no priced open-market purchases or sales on record, so none of these filings shows a decision to buy or sell shares in the market.
No transactions found
Try adjusting your filters or search criteria